GrB-Fc-CEA

GrB-Fc-CEA is a preclinical-stage recombinant fusion protein developed by AbBC Therapies using its proprietary Targeted Granzyme B Immunotherapy (TGI) platform. The therapeutic is designed to target carcinoembryonic antigen (CEA), a tumor-associated antigen overexpressed in various solid tumors, including colorectal, lung, and breast cancers. The drug consists of an active human granzyme B enzyme fused to an antibody targeting CEA via an Fc (immunoglobulin heavy chain) domain. Its mechanism of action involves high-affinity binding to CEA-expressing tumor cells, followed by internalization and the release of granzyme B into the cytoplasm. Once intracellular, granzyme B triggers the pro-apoptotic caspase cascade, inducing programmed cell death. This approach aims to leverage the natural cytotoxic mechanisms of the immune system without the requirement for chemical linkers or synthetic toxins.

Other names

Granzyme B-Fc-CEA fusion protein